Multi-omics analysis identifies stemness-driven molecular subtypes, prognostic signature, epigenetic target APCDD1, and drug candidate Leflunomide in Wilms tumor - Scorecard - MDSpire

Multi-omics analysis identifies stemness-driven molecular subtypes, prognostic signature, epigenetic target APCDD1, and drug candidate Leflunomide in Wilms tumor

  • By

  • Huifang Du

  • Yifeng Zheng

  • Chentao Zhu

  • Yang Guo

  • Pengfei Li

  • Peng Hong

  • May 25, 2026

  • 0 min

Share

Clinical Scorecard: Comprehensive Multi-Omics Investigation Reveals Stemness-Related Molecular Subtypes, Prognostic Indicators, Epigenetic Target APCDD1, and Potential Therapeutic Agent Leflunomide in Wilms Tumor

At a Glance

CategoryDetail
Condition
Key MechanismsStemness features, tumor microenvironment, epigenetic regulation
Target Population
Care Setting

Key Highlights

    Guideline-Based Recommendations

    Diagnosis

      Management

        Monitoring & Follow-up

          Risks

            Patient & Prescribing Data

            Clinical Best Practices

              Related Resources & Content

              Original Source(s)

              Multi-omics analysis identifies stemness-driven molecular subtypes, prognostic signature, epigenetic target APCDD1, and drug candidate Leflunomide in Wilms tumor

              • by Huifang Du, Yifeng Zheng, Chentao Zhu, Yang Guo, Pengfei Li, Peng Hong

              • May 25, 2026

              Related Content

              Management of toxicities from antibody – drug conjugates in breast cancer

              Biotech exec Jeremy Levin on the industry’s strategic turning point

              FOXA2 in cancer: from fundamental biology to clinical translation